Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 13, Number 2—February 2007

Research

Neutralizing Antibodies after Infection with Dengue 1 Virus

Gustavo Kourí*Comments to Author , Mayling Alvarez*, Rosmari Rodriguez-Roche*, Lídice Bernardo*, Tibaire Montes†, Susana Vazquez*, Luis Morier*, Angel Alvarez*, Ernest A Gould‡, Maria G. Guzman*Comments to Author , and Scott B Halstead§
Author affiliations: *“Pedro Kourí” Tropical Medicine Institute, Havana, Cuba; †Instituto Medicina Tropical, Caracas, Venezuela; ‡Centre for Ecology and Hydrology, Oxford, United Kingdom; §Pediatric Dengue Vaccine Initiative, Bethesda, Maryland, USA;

Main Article

Table 1

Dengue virus strains used in this study

SerotypeStrainPassage no.*Place and year of isolation
DENV-1†Angola4PC6/36 1PVero 1PC6/36Angola, 1988
DENV-2‡A15/814PMB 4PC6/36Cuba, 1981
DENV-2†‡I3486004P C6/36Colombia, 1986
DENV-3116/003P C6/36Cuba, 2000
DENV-4†Dominica7P C6/36Dominica, 1981

**P, passage; C6/36, Aedes albopictus cell line; Vero, green monkey kidney cell line; MB, mouse brain.

†DENV, dengue virus; received from Robert Shope, University of Texas Medical Branch, Galveston, Texas, USA.

‡DENV-2, A15/81 strain (Asian genotype), DENV 2, I348600 (American genotype).

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO